RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB

BACKGROUND: Ependymoma is a rare tumor for which the role of chemotherapy has not been established either for newly diagnosed or recurrent disease. We report on the first prospective adult clinical trial of chemotherapy for recurrent ependymoma. METHODS: Adult (> 18 years) were treated with dose-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Armstrong, Terri, Yuan, Ying, Wu, Jimin, Mendoza, Tito, Vera, Elizabeth, Omuro, Antonio, Lieberman, Frank, Robins, H, Gerstner, Elizabeth, Wu, Jing, Wen, Patrick, Mikkelsen, Tom, Aldape, Kenneth, Gilbert, Mark
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217700/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.998
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars